A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care. …
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - - Australian Biotech -
Medibank funding expansion signals momentum for Emyria’s mental health model
February 16, 2026 - - Latest News -
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 - - Latest News -
Chimeric Therapeutics names experienced biotech leader as chair in board and executive refresh
February 16, 2026 - - Australian Biotech -
'It’s the first time in over 30 years that a new way of administering adrenaline has been approved in Australia'
February 16, 2026 - - Latest News -
Rare Cancers Australia sets sights on 2026 Kosi Challenge with renewed fundraising momentum
February 15, 2026 - - Latest News -
PBS spending is driven less by explicit fiscal choices and more by the flow of recommendations
February 15, 2026 - - Latest News